

Artificial Blood and Plasma: Global Markets to 2027

<https://marketpublishers.com/r/ACAC59C32D5EN.html>

Date: March 2018

Pages: 240

Price: US\$ 1,375.00 (Single User License)

ID: ACAC59C32D5EN

Abstracts

Report Scope:

The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products. The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.

The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included. Excluded from consideration are product physical and chemical properties, detailed and unpublished clinical/lab results on the products, and detailed methodology/techniques used for product production.

Report Includes:

144 tables

An overview of global market for artificial blood plasma

Analyses of global market trends, with projections of compound annual growth rates (CAGRs) through 2027

Identification of growth-driving factors influencing the artificial blood plasma

market, as well as opportunities, restraints, and technological developments

Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Contribution of the Study and Intended Audience
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts' Credentials
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

Introduction

CHAPTER 3 MARKET OVERVIEW

Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing With the Risks of Infection
Artificial Blood Will Help to Decrease the Load on Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Artificial Blood Has the Potential to Lower Costs of the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Challenges in Artificial Blood Development

CHAPTER 4 MARKET ESTIMATION

Market Dynamics: Factors and Impact Analysis
Time factor
Product Preference
Regulatory Approvals
Product Demand

Product Acceptance
Cost and Effectiveness
Intense Competition in the Market
Clinical Trials
Technologies
Product Pricing
Patient Group
Global Potential Market
Surgeries and Death Cases
Market Penetration

CHAPTER 5 MARKET BY SOURCE

Introduction
Artificial Blood Developed From Human Blood
Artificial Blood Developed From Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin

CHAPTER 6 MARKET BY TYPE

Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin Based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: - Hemoglobin Solutions

CHAPTER 7 MARKET BREAKDOWN BY APPLICATION

Introduction
Surgeries

Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Global Potential Artificial Blood Market, by Application

CHAPTER 8 MARKET BREAKDOWN BY REGION

Introduction
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Asia Pacific
China
India
Japan
Australia
Rest of The World
Brazil
South Africa

CHAPTER 9 REGULATION AND PATENT REVIEW

Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Review

CHAPTER 10 COMPETITIVE LANDSCAPE

Introduction

CHAPTER 11 PRODUCT ANALYSIS

Introduction

Product Safety

Product Effectiveness

Product Cost

Legal Implications

Hemolink

Product offered by Hemosol BioPharma Inc.

Clinical Trials

HemAssist

Product offered by Baxter Healthcare Corp.

Hemopure

Product offered by Biopure Corp./OPK Biotech

Clinical Trials

HemoSpan

Product offered by Sangart, Inc.

Clinical Trials

HemoTech

Product offered by HemoBioTech, Inc.

Clinical Trials

DDFPe

Product offered by NuvOx Pharma LLC

Oxycyte

Product offered by Tenax Therapeutics Inc.

Clinical Trials

Oxygent

Product offered by Alliance Pharmaceutical Corp.

Clinical Trials

VIDAPHOR

Product offered by FluorO2 Therapeutics, Inc.

Clinical Trials

PHER-O2

Product offered by Sanguine Biosciences

Clinical Trials

POLYHEME

Product Offered by Northfield Laboratories Inc.
Clinical Trials

SANGUINATE

Product Offered by Prolong Pharmaceuticals, LLC
Clinical Trials

CHAPTER 12 COMPANY PROFILES

ALLIANCE PHARMACEUTICAL CORP

Business Overview
Company and Product Developments

BAXTER HEALTHCARE CORP.

Business Overview
Company and Product Developments

BIOPURE CORP.

Business Overview

FLUORO2 THERAPEUTICS,INC.

Business Overview
Company and Product Developments

HEMOBIOTECH, INC.

Business Overview
Company and Product Developments

NORTHFIELD LABORATORIES INC.

Business Overview
Company and Product developments

NUVOX PHARMA LLC.

Business Overview
Company and Product Developments

PROLONG PHARMACEUTICALS, LLC

Business Overview
Company and Product Developments

SANGART, INC.

Business Overview

SANGUINE BIOSCIENCES

Business Overview
Company and Product Developments

TENAX THERAPEUTICS INC.

Business Overview
Company and Product Developments

THERAPURE BIOPHARMA INC.

Business Overview
Company and Product Developments

CHAPTER 13 APPENDIX

List Of Tables

LIST OF TABLES

Summary Table: Global Potential Artificial Blood Market by case type, Through 2027

Table 1: Historical Events Related to Blood Transfusion

Table 2: Potential Benefits and Application Areas of Artificial Blood

Table 3: The Challenges Associated With the Development of Artificial Blood

Table 4: Average Number of Blood Units Required During Particular Medical Condition

Table 5: Market Penetration Cases Based on Set of Assumptions

Table 6: Global Potential Artificial Blood Market by Case Type, Through 2027

Table 7: Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions

Table 8: Pros and Cons of Artificial Blood Developed from Human Blood

Table 9: Pros and Cons of Artificial Blood Developed from Animal Blood

Table 10: Pros & Cons of Artificial Blood Developed from Recombinant Blood

Table 11: Summary of Acellular Hb-Based Oxygen Carriers

Table 12: Hemoglobin Based Oxygen Carrier Products and Approval Status

Table 13: Potential Clinical Applications of Oxygen Carriers

Table 14: Composition of PFC Emulsion Based Artificial Blood Products

Table 15: First-Generation Perfluorocarbon Emulsions Used in Medicine and Biology

Table 16: Comparative Study of Second-Generation PFCs

Table 17: PFC Emulsion Products and Current Status

Table 18: Comparative Study Between RBCs and HBOCs

Table 19: HBOC Solutions Transfusion: Side Effects and Possible Causes

Table 20: HBOC Products Developed by Various Companies

Table 21: Global Potential Artificial Blood Market, by Application, Through 2027

Table 22: United States: Potential Artificial Blood Market, Through 2027

Table 23: Canada: Potential Artificial Blood Market, Through 2027

Table 24: Mexico: Potential Artificial Blood Market, Through 2027

Table 25: Germany: Potential Artificial Blood Market, Through 2027

Table 26: France: Potential Artificial Blood Market, Through 2027

Table 27: U.K.: Potential Artificial Blood Market, Through 2027

Table 28: Italy: Potential Artificial Blood Market, Through 2027

Table 29: Spain: Potential Artificial Blood Market, Through 2027

Table 30: Russia: Potential Artificial Blood Market, Through 2027

Table 31: China: Potential Artificial Blood Market, Through 2027

Table 32: India: Potential Artificial Blood Market, Through 2027

Table 33: Japan: Potential Artificial Blood Market, Through 2027

Table 34: Australia: Potential Artificial Blood Market, Through 2027

- Table 35: Brazil: Potential Artificial Blood Market, Through 2027
- Table 36: South Africa: Potential Artificial Blood Market, Through 2027
- Table 37: Summary of Three Clinical Trial Phases Recognized by FDA
- Table 38: Hemolink: Raw Material and Method Overview
- Table 39: Hemolink: Advantages and Disadvantages
- Table 40: Hemolink Clinical Trials Details
- Table 41: Hemolink Clinical Trial: Tracking Information
- Table 42: Hemolink Clinical Trial: Descriptive Information
- Table 43: Hemolink Clinical Trial: Recruitment Information
- Table 44: Hemolink Clinical Trial: Administrative Information
- Table 45: HemAssist: Raw Material and Method Overview
- Table 46: HemAssist: Product Characteristics
- Table 47: HemAssist: Advantages and Disadvantages
- Table 48: Hemopure: Raw Material and Method Overview
- Table 49: Hemopure: Product Characteristics
- Table 50: Hemopure: Advantages and Disadvantages
- Table 51: Hemopure: List of Clinical Trials Registered
- Table 52: Hemopure Clinical Trial: Patient Information
- Table 53: Hemopure Clinical Trial: Details
- Table 54: Summary of the Red-Blood-Cell-Controlled Phase 2 and Phase 3 Clinical Trial Performed by Biopure Corp.
- Table 55: Red-Blood-Cell-Controlled Clinical Trial Performed on Surgical Patients, by Dosage and Effects
- Table 56: Hemopure Clinical Trial: Tracking Information
- Table 57: Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
- Table 58: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
- Table 59: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Amputation At/Below Knee from Critical Lower Limb Ischemia
- Table 60: A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects
- Table 61: Descriptive Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
- Table 62: Recruitment Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
- Table 63: Administrative Information of Hemopure Clinical Trial for HBOC-201 in Trauma Subjects
- Table 64: Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia

Table 65: Tracking Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia

Table 66: Descriptive Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia

Table 67: Recruitment Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia

Table 68: Administrative Information of Hemopure Clinical Trial for the Treatment of Life-Threatening Anemia

Table 69: Hemospan: Raw Material and Method Overview

Table 70: Hemospan: Product Characteristics

Table 71: Hemospan: Advantages and Disadvantages

Table 72: Clinical Studies with Hemospan: Completed and Ongoing

Table 73: Hemospan Clinical Trial: Details

Table 74: Hemospan Clinical Trial: Tracking Information

Table 75: Hemospan Clinical Trial: Descriptive Information

Table 76: Hemospan Clinical Trial: Recruitment Information

Table 77: Hemospan Clinical Trial: Administrative Information

Table 78: Hemotech: Raw Material and Method Overview

Table 79: HemoTech: Advantages and Disadvantages

Table 80: HemoTech Clinical Trials: Details

Table 81: HemoTech Clinical Trial: Tracking Information

Table 82: HemoTech Clinical Trial: Descriptive Information

Table 83: HemoTech Clinical Trial: Recruitment Information

Table 84: HemoTech Clinical Trial: Administrative Information

Table 85: DDFPe: Company Product Range and Description

Table 86: DDFPe: Raw Material and Method Overview

Table 87: DDFPe: Advantages and Disadvantages

Table 88: DDFPe Clinical Trials: Details

Table 89: DDFPe Clinical Trial: Tracking Information

Table 90: DDFPe Clinical Trial: Descriptive Information

Table 91: DDFPe Clinical Trial: Recruitment Information

Table 92: DDFPe Clinical Trial: Administrative Information

Table 93: Oxycyte: Raw Material and Method Overview

Table 94: Oxycyte: Advantages and Disadvantages

Table 95: Oxycyte Clinical Trials: Details

Table 96: Oxycyte Clinical Trial: Tracking Information

Table 97: Descriptive Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)

Table 98: Recruitment Information of Clinical Trial for Safety and Tolerability of Oxycyte

in Patients with Traumatic Brain Injury (TBI)

Table 99: Administrative Information of Clinical Trial for Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury (TBI)

Table 100: Details of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury

Table 101: Tracking Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury

Table 102: Descriptive Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury

Table 103: Recruitment Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury

Table 104: Administrative Information of Clinical Trial for Study of Oxycyte in Severe Closed Head Injury

Table 105: Oxygent: Raw Material and Method Overview

Table 106: Oxygent: Advantages and Disadvantages

Table 107: Oxygent: Clinical Trials

Table 108: Vidaphor: Raw Material and Method Overview

Table 109: Vidaphor: Advantages and Disadvantages

Table 110: Vidaphor: Clinical Trial

Table 111: PHER-O2: Raw Material and Method Overview

Table 112: PHER-O2: Advantages and Disadvantages

Table 113: PHER-O2: Clinical Trials

Table 114: PolyHeme: Raw Material and Method Overview

Table 115: PolyHeme: Product Characteristics

Table 116: PolyHeme: Advantages and Disadvantages

Table 117: Polyheme Clinical Trials: Patient Information

Table 118: PolyHeme Clinical Trial: Details

Table 119: PolyHeme Clinical Trial: Tracking Information

Table 120: PolyHeme Clinical Trial: Descriptive Information

Table 121: PolyHeme Clinical Trial: Recruitment Information

Table 122: PolyHeme Clinical Trial: Administrative Information

Table 123: SANGUINATE: Raw Material and Method Overview

Table 124: SANGUINATE: Advantages and Disadvantages

Table 125: SANGUINATE: Clinical Trials

Table 126: SANGUINATE Clinical Trial: Details

Table 127: SANGUINATE Clinical Trial: Tracking Information

Table 128: SANGUINATE Clinical Trial: Descriptive Information

Table 129: SANGUINATE Clinical Trial: Recruitment Information

Table 130: SANGUINATE Clinical Trial: Administrative Information

Table 131: Alliance Pharmaceutical Corp: Company and Product Snapshot

Table 132: Baxter International Inc.: Company and Product Snapshot

Table 133: Biopure Corp: Company and Product Snapshot

Table 134: FluorO2 Therapeutics Inc.: Company and Product Snapshot

Table 135: HemoBioTech, Inc.: Company and Product Snapshot

Table 136: HemoBioTech, Inc.: Company and Product Snapshot

Table 137: Northfield Laboratories Inc.: Company and Product Snapshot

Table 138: Prolong Pharmaceuticals, LLC: Company and Product Snapshot

Table 139: Sangart, Inc: Company and Product Snapshot

Table 140: Sanguine Biosciences: Company and Product Snapshot

Table 141: Tenax Therapeutics, Inc.: Company and Product Snapshot

Table 142: Therapure Biopharma Inc.: Company and Product Snapshot

Table 143: Abbreviations Used in Artificial Blood Market

List Of Figures

LIST OF FIGURES

Summary Figure: Global Potential Artificial Blood Market, 2022–2027

Figure 1: Medical Applications of Human Red Blood Cells

Figure 2: Total Number of Surgeries and Death Cases in the World, 2017–2022

Figure 3: Total Number of Blood Units Transfused in the World, 2017–2027

Figure 4: Global Potential Artificial Blood Market, 2022–2027

Figure 5: Artificial Blood Manufactured from Different Sources

Figure 6: Historical Events of HBOCs Developed Using Recombinant Technology

Figure 7: Classification of Modified Hemoglobin Solution Based on Methods

Figure 8: Classification of Different Types of Oxygen Carriers

Figure 9: Generations of Perfluorocarbon Emulsions

Figure 10: Advantages and Disadvantages of PFC Emulsions

Figure 11: Development of HBOCs

Figure 12: Advantages and Disadvantages of HBOCs

Figure 13: Global Potential Artificial Blood Market, by Application, 2022–2027

Figure 14: United States: Country Snapshot

Figure 15: Heart Disease Trend in the United States

Figure 16: Cancer Disease Trend in the United States

Figure 17: Transport Accident Trend in the United States

Figure 18: Blood Supply in the United States

Figure 19: Blood Demand in the United States

Figure 20: United States: Potential Artificial Blood Market, 2022–2027

Figure 21: Canada: Country Snapshot

Figure 22: Heart Disease Trend in Canada

Figure 23: Cancer Disease Trend in Canada

Figure 24: Transport Accident Trend in Canada

Figure 25: Blood Supply in Canada

Figure 26: Blood Demand in Canada

Figure 27: Canada: Potential Artificial Blood Market, 2022–2027

Figure 28: Mexico: Country Snapshot

Figure 29: Heart Disease Trend in Mexico

Figure 30: Cancer Disease Trend in Mexico

Figure 31: Transport Accident Trend in Mexico

Figure 32: Blood Supply in Mexico

Figure 33: Blood Demand in Mexico

Figure 34: Mexico: Potential Artificial Blood Market, 2022–2027

- Figure 35: Germany: Country Snapshot
- Figure 36: Heart Disease Trend in Germany
- Figure 37: Cancer Disease Trend in Germany
- Figure 38: Transport Accident Trend in Germany
- Figure 39: Blood Supply in Germany
- Figure 40: Blood Demand in Germany
- Figure 41: Germany: Potential Artificial Blood Market, 2022–2027
- Figure 42: France: Country Snapshot
- Figure 43: Heart Disease Trend in France
- Figure 44: Cancer Disease Trend in France
- Figure 45: Transport Accident Trend in France
- Figure 46: Blood Supply in France
- Figure 47: Blood Demand (RBCs Transfused) in France
- Figure 48: France: Potential Artificial Blood Market, 2022–2027
- Figure 49: United Kingdom: Country Snapshot
- Figure 50: Heart Disease Trend in the U.K.
- Figure 51: Cancer Disease Trend in the U.K.
- Figure 52: Transport Accident Trend in the U.K.
- Figure 53: Blood Supply in the U.K.
- Figure 54: Blood Demand in the U.K.
- Figure 55: U.K.: Potential Artificial Blood Market, 2022–2027
- Figure 56: Italy: Country Snapshot
- Figure 57: Heart Disease Trend in Italy
- Figure 58: Cancer Disease Trend in Italy
- Figure 59: Transport Accident Trend in Italy
- Figure 60: Blood Supply in Italy
- Figure 61: Blood Demand in Italy
- Figure 62: Italy: Potential Artificial Blood Market, 2022–2027
- Figure 63: Spain: Country Snapshot
- Figure 64: Heart Disease Trend in Spain
- Figure 65: Cancer Disease Trend in Spain
- Figure 66: Transport Accident Trend in Spain
- Figure 67: Blood Supply in Spain
- Figure 68: Blood Demand in Spain
- Figure 69: Spain: Potential Artificial Blood Market, 2022–2027
- Figure 70: Russia: Country Snapshot
- Figure 71: Heart Disease Trend in Russia
- Figure 72: Cancer Disease Trend in Russia
- Figure 73: Transport Accident Trend in Russia

- Figure 74: Blood Supply in Russia
- Figure 75: Blood Demand in Russia
- Figure 76: Russia: Potential Artificial Blood Market, 2022–2027
- Figure 77: China: Country Snapshot
- Figure 78: Heart Disease Trend in China
- Figure 79: Cancer Disease Trend in China
- Figure 80: Transport Accident Trend in China
- Figure 81: Blood Supply in China
- Figure 82: Blood Demand in China
- Figure 83: China: Potential Artificial Blood Market, 2022–2027
- Figure 84: India: Country Snapshot
- Figure 85: Heart Disease Trend in India
- Figure 86: Cancer Disease Trend in India
- Figure 87: Transport Accident Trend in India
- Figure 88: Blood Supply in India
- Figure 89: Blood Demand in India
- Figure 90: India: Potential Artificial Blood Market, 2022–2027
- Figure 91: Japan: Country Snapshot
- Figure 92: Heart Disease Trend in Japan
- Figure 93: Cancer Disease Trend in Japan
- Figure 94: Transport Accident Trend in Japan
- Figure 95: Blood Supply in Japan
- Figure 96: Blood Demand in Japan
- Figure 97: Japan: Potential Artificial Blood Market, 2022–2027
- Figure 98: Australia: Country Snapshot
- Figure 99: Heart Disease Trend in Australia
- Figure 100: Cancer Disease Trend in Australia
- Figure 101: Transport Accident Trend in Australia
- Figure 102: Blood Supply in Australia
- Figure 103: Blood Demand in Australia
- Figure 104: Australia: Potential Artificial Blood Market, 2022–2027
- Figure 105: Brazil: Country Snapshot
- Figure 106: Heart Disease Trend in Brazil
- Figure 107: Cancer Disease Trend in Brazil
- Figure 108: Transport Accident Trend in Brazil
- Figure 109: Blood Supply in Brazil
- Figure 110: Blood Demand in Brazil
- Figure 111: Brazil: Potential Artificial Blood Market, 2022–2027
- Figure 112: South Africa: Country Snapshot

Figure 113: Heart Disease Trend in South Africa

Figure 114: Cancer Disease Trend in South Africa

Figure 115: Transport Accident Trend in South Africa

Figure 116: Blood Supply in South Africa

Figure 117: Blood Demand in South Africa

Figure 118: South Africa: Potential Artificial Blood Market, 2022–2027

Figure 119: Current Competition in the Global Artificial Blood Market (I), 2020–2022

Figure 120: Current Competition in the Global Artificial Blood Market (II), 2022–2027

Figure 121: Artificial Blood: Parameters for Product Analysis

Figure 122: Hemolink: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)

Figure 123: HemAssist: Production Flow Chart

Figure 124: HemAssist: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)

Figure 125: Hemopure: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)

Figure 126: Hemospan: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

Figure 127: HemoTech: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)

Figure 128: DDFPe: Product Analysis (Based on Safety, Effectiveness, Cost, and Legal Implications)

Figure 129: Oxycyte: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

Figure 130: Oxygent: Product Analysis (Based on Safety, Effectiveness, Cost, And Legal Implications)

Figure 131: Vidaphor: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

Figure 132: PHER-O2: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

Figure 133: PolyHeme: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

Figure 134: SANGUINATE: Product Analysis (Based on Safety, Effectiveness, Cost and Legal Implications)

I would like to order

Product name: Artificial Blood and Plasma: Global Markets to 2027

Product link: <https://marketpublishers.com/r/ACAC59C32D5EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ACAC59C32D5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970